FIELD: chemistry.
SUBSTANCE: group of inventions relates to novel GLP-1 and/or GLP-2 receptor agonists. Disclosed is a compound containing a sequence of formula (1a) or formula (1b):
where S, T, W, Z, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, AA10, AA11, AA12, AA13, AA14, AA15, A16, AA17, AA18, AA19, AA20, AA21, AA22, Sa, Ta, Wa, Xa, Ya, Za, AA1a, AA2a, AA3a, AA4a, AA5a, AA6a, AA7a, AA8a, AA9a, AA10a, AA11a, AA12a, AA13a, AA14a, AA15a, A16a, R, R1 and R2 are defined in the patent claim, or its tautomeric or stereochemically isomeric form, or its prodrug, salt or zwitterion. Also disclosed is a pharmaceutical composition having GLP-1 and/or GLP-2 receptor agonist activity.
EFFECT: group of inventions provides treating, preventing, relieving, controlling or reducing the risk of disorders associated with glucagon-like peptide (GLP) receptors.
22 cl, 5 ex, 3 tbl
Title | Year | Author | Number |
---|---|---|---|
GLP RECEPTOR AGONISTS | 2021 |
|
RU2838225C1 |
PEPTIDE DRUGS WITH HIGH EFFECTIVENESS AGAINST INSULIN RESISTANCE | 2012 |
|
RU2602801C2 |
NOVEL GLUCAGON ANALOGUES | 2011 |
|
RU2559320C2 |
COMPOUNDS | 2016 |
|
RU2725616C2 |
PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
BENZOTHIAZEPINE COMPOUNDS AND USE THEREOF AS BILE ACID MODULATORS | 2020 |
|
RU2838460C1 |
BENZOTHIA(DI)AZEPINE COMPOUNDS AND USE THEREOF AS BILE ACID MODULATORS | 2020 |
|
RU2827704C1 |
ANTIBODY AND DRUG CONJUGATES (ADC) AND ANTIBODY AND PRODRUG CONJUGATES (APDC) CONTAINING ENZYMATICALLY CLEAVABLE GROUPS | 2016 |
|
RU2751512C2 |
GLUCAGON ANALOGUES, POSSESSING HIGHER SOLUBILITY AND STABILITY IN BUFFERS WITH PHYSIOLOGICAL Ph VALUES | 2009 |
|
RU2560254C2 |
CONJUGATE ANTIBODY-DERIVATIVE OF PYRROLOBENZODIAZEPINE | 2018 |
|
RU2820928C2 |
Authors
Dates
2025-03-17—Published
2021-03-16—Filed